Short-term effects of elexacaftor/tezacaftor/ivacaftor in pediatric cystic fibrosis patients in Brazil: a case series
2024

Short-term effects of ETI in pediatric cystic fibrosis patients in Brazil

Sample size: 3 publication Evidence: moderate

Author Information

Author(s): Amor-Barbosa Marta, Vendrusculo Fernanda Maria, Epifanio Matias, Donadio Marcio Vinicius Fagundes, Pinto Leonardo Araujo

Primary Institution: Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

Hypothesis

What are the short-term effects of elexacaftor/tezacaftor/ivacaftor therapy in pediatric cystic fibrosis patients?

Conclusion

The study shows positive impacts of ETI therapy on lung function and symptom improvement in pediatric cystic fibrosis patients.

Supporting Evidence

  • Patients showed significant improvements in lung function after starting ETI therapy.
  • One patient experienced complete regression of nasal polyps.
  • None of the patients reported adverse effects from the treatment.

Takeaway

This study looked at how a new treatment helped kids with cystic fibrosis breathe better and feel less sick.

Methodology

Case series of pediatric patients treated with ETI therapy, monitoring lung function and symptoms.

Potential Biases

Potential bias due to the small sample size and lack of control group.

Limitations

The study is based on a small number of cases and lacks long-term follow-up data.

Participant Demographics

Three pediatric patients with varying CFTR gene mutations.

Digital Object Identifier (DOI)

10.36416/1806-3756/e20230403

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication